Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Aravive Biologics’ Treatment For Platinum-Resistant Recurrent Ovarian Cancer Receives Fast Track Designation
Aravive Biologics’ Treatment For Platinum-Resistant Recurrent Ovarian Cancer Receives Fast Track Designation
Aravive Biologics’ Treatment For Platinum-Resistant Recurrent Ovarian Cancer Receives Fast Track Designation
Submitted by
admin
on August 20, 2018 - 9:58am
Source:
CP Wire
News Tags:
Aravive Biologics
AVB-S6-500
ovarian cancer
platinum-resistant ovarian cancer
Headline:
Aravive Biologics’ Treatment For Platinum-Resistant Recurrent Ovarian Cancer Receives Fast Track Designation
snippet:
Ph I trial showed reduction in biomarker associated with anti-tumor activity in animal models
There were no serious or dose-limiting adverse events in the Ph I trial
Aravive has a manufacturing collaboration with WuXi for AVB-S6-500
Do Not Allow Advertisers to Use My Personal information